CDMOs in France: 15 compared (2026)
15 of the 255 contract development and manufacturing organisations in A4BEE’s European census are headquartered in France. The largest, with revenue over €1bn, are Seqens. 6 sit between €250m and €1bn and 8 are smaller or niche.
By ownership: 4 family-owned, 4 private equity, 3 listed and 4 part of a pharma or industrial group. The most common capabilities are small-molecule API (5), sterile fill-finish (5), oral solid dose (4), peptide (3) and biologics and biosimilars (3). 9 of the 15 rows rest on audited reports or official company disclosures; the rest come from secondary sources or estimates.
15 companies
CDMOs in France
| Company | HQ | Ownership | Size | Revenue (as reported) | Modalities | Data |
|---|---|---|---|---|---|---|
| SeqensLarge API/small-molecule CDMO plus specialty ingredients; ~200 APIs. Revenue includes non-pharma specialty ingredients. | Écully | Private equitySK Capital | Tier 1 | ~€1.1 bn (group) | Small-molecule API, Peptide | high |
| Delpharm | Boulogne | Family-owned | Tier 2 | ~€650 m | Oral solid dose, Sterile fill-finish, Biologics and biosimilars | medium |
| EthypharmHybrid specialty pharma + CDMO; CDMO arm specializes in controlled substances, HPAPIs and modified-release oral. | Saint-Cloud | Private equityPAI Partners | Tier 2 | €135 m (2024, SAS) | Oral solid dose, Small-molecule API | medium |
| EUROAPIEuronext Paris; Sanofi ~30% + Bpifrance. ~200 small-molecule APIs plus peptides and oligos. | Paris | Listed | Tier 2 | €911.9 m (2024), −10% | Small-molecule API, Peptide | low |
| Just-Evotec BiologicsEvotec's biologics CDMO arm; J.POD Toulouse opened 2024 as its first EU facility. Distinct from the small-molecule Aptuit (Evotec) site. | Toulouse | ListedEvotec | Tier 2 | not disclosed | Monoclonal antibody, Biologics and biosimilars | medium |
| MinakemAPI and HPAPI CDMO (custom synthesis). Brand of the privately-held Minafin Group. | Dunkerque | Family-ownedMinafin Group | Tier 2 | not disclosed | Small-molecule API | medium |
| Unither PharmaceuticalsWorld leader in Blow-Fill-Seal sterile unit-dose liquids; also effervescent/oral formats. | Amiens | Private equityArdian | Tier 2 | €371 m (2022) | Sterile fill-finish, Oral solid dose | high |
| ABL EuropeViral-vector CDMO (adeno, lenti, AAV, pox/MVA). Acquired by Oxford Biomedica in 2024. | Lyon | ListedOxford Biomedica | Tier 3 | not disclosed | Viral vector and vaccine, Cell and gene therapy | high |
| Amatsigroup (Eurofins)French sterile CDMO within the Eurofins network. | Toulouse | Part of a pharma or industrial groupEurofins | Tier 3 | n/d | Sterile fill-finish | low |
| Cell-EasyCell-therapy CDMO (T/NK, MSCs, HSCs; autologous & allogeneic). Proprietary CellReady MSC platform. | Toulouse | Family-owned | Tier 3 | not disclosed | Cell and gene therapy | high |
| CenexiSterile fill-finish specialist (injectables, ampoules, HPAPI sterile). | Fontenay-sous-Bois | Private equityCathay Capital | Tier 3 | €191 m (2023) | Sterile fill-finish | high |
| GTP BiowaysBiologics CDMO (mAbs, proteins, nanodrugs, ADCs, fill-finish). Acquired by Italy's Olon; now Olon France. | Toulouse | Part of a pharma or industrial groupOlon Group | Tier 3 | ~€12 m | Monoclonal antibody, Biologics and biosimilars, Antibody-drug conjugate (ADC), Microbial and protein, Sterile fill-finish | high |
| PMC IsochemCustom API and peptide CDMO. Acquired by PMC Group (US) in 2017. | Vert-le-Petit | Part of a pharma or industrial groupPMC Group | Tier 3 | not disclosed | Small-molecule API, Peptide | high |
| SkyepharmaComplex oral-solid-dose specialist (modified-release, multi-layer/press-coated tablets). Management-owned. | Saint-Quentin-Fallavier | Family-ownedOléron Pharma | Tier 3 | ~€20 m+ (site) | Oral solid dose | high |
| YposkesiCell & gene therapy CDMO (AAV + lentiviral vectors). Spun out of Genethon; SK pharmteco majority. | Corbeil-Essonnes | Part of a pharma or industrial groupSK pharmteco | Tier 3 | not disclosed | Cell and gene therapy, Viral vector and vaccine | high |
Size: Tier 1 (revenue over €1bn) · Tier 2 (€250m–€1bn) · Tier 3 (under €250m or niche).
Revenue, staff and site figures are as reported and mix audited accounts with commercial estimates, which are often wrong for private companies. Each row carries a confidence mark; verify a figure before quoting it.
Browse the census
Other European CDMO lists
By country
- CDMOs in Italy (31)
- CDMOs in Spain (30)
- CDMOs in Germany (28)
- CDMOs in the United Kingdom (25)
- CDMOs in France
- CDMOs in Switzerland (14)
- CDMOs in Poland (11)
- CDMOs in Belgium (9)
- CDMOs in Sweden (9)
- CDMOs in Greece (8)
- CDMOs in Ireland (8)
- CDMOs in the Netherlands (8)
- CDMOs in Portugal (8)
- CDMOs in Denmark (7)
- CDMOs in Austria (5)
- CDMOs in Finland (5)
- CDMOs in Norway (5)
- CDMOs in Czechia (4)
- CDMOs in Lithuania (4)
- CDMOs in Bulgaria (3)
By modality
- Small-molecule API CDMOs in Europe (107)
- Oral solid dose CDMOs in Europe (94)
- Sterile fill-finish CDMOs in Europe (106)
- Biologics and biosimilars CDMOs in Europe (66)
- Monoclonal antibody CDMOs in Europe (36)
- Antibody-drug conjugate (ADC) CDMOs in Europe (15)
- Cell and gene therapy CDMOs in Europe (29)
- mRNA and LNP CDMOs in Europe (22)
- Viral vector and vaccine CDMOs in Europe (32)
- Microbial and protein CDMOs in Europe (34)
- Peptide CDMOs in Europe (24)